# V1 Empirics Check — x-ai/grok-4.1-fast (Variant C)

**Model:** x-ai/grok-4.1-fast
**Variant:** C
**Date:** 2026-03-29T13:22:58.513108

---

### 1. Idea Fidelity
The paper faithfully pursues the original idea manifest, centering on Florida's pill mill crackdown (HB 7095) as the anchor policy with an event study using county-month ARCOS data aggregated for Florida (treated) versus Georgia/Alabama (controls). It constructs the novel outcomes exactly as specified—high-dose oxycodone share (≥30mg), average mg per pill, and oxycodone/hydrocodone ratio—and emphasizes dosage-strength composition shifts (not volume) to reveal diverted opioid demand structure. Key elements like transaction-level ARCOS (178.6M records), monthly granularity, pill weighting for high-volume counties, and the boom-bust pattern in Florida (26%→54%→31% high-dose share) are all executed. The only minor deviation is the absence of the "broader analysis" via Callaway-Sant'Anna (2021) on staggered PDMPs, but the manifest positions Florida as the core case.

### 2. Summary
This paper documents a novel dosage-strength composition shift in oxycodone shipments following Florida's 2011 pill mill crackdown, using county-month ARCOS data in a pill-weighted difference-in-differences event study with Georgia/Alabama controls. The high-dose share (≥30mg) falls 9.3 percentage points (39% relative to pre-treatment mean), driven by high-volume counties, revealing that pill mills disproportionately supplied diversion-preferred high-dose pills. This separates diversion from legitimate demand, with policy implications for early-warning surveillance via composition monitoring.

### 3. Essential Points
1. **Inference with few clusters undermines credibility.** State-level clustering (only 3 clusters: FL, GA, AL) produces implausibly precise SEs (e.g., 0.0079 for β=-0.0927), violating asymptotic assumptions. The permutation test is a step forward but yields a floor p=1/3; without wild cluster bootstrap (WCB) or synthetic controls for pre-trends, p-values cannot be trusted. Authors must implement WCB (e.g., Radelet-MacKinnon) or Anderson-Rubin tests and lead with point estimates/event patterns only if inference fails.

2. **Parallel trends violation requires stronger falsification.** Positive pre-trends (e.g., +6.4pp at t-5) reflect the "boom," but this violates standard DiD assumptions over the full sample. The post-reversal is compelling visually, but absent synthetic control matching (Abadie et al. 2010) or triple differences (e.g., interacting with county volume terciles), it's hard to rule out Florida-specific confounders (e.g., national reformulation spillovers). Restrict to 2009+ pre-period strengthens results but doesn't resolve; add SCM or Sun-Abraham (2021) staggered DiD for pre-trend diagnostics.

3. **Control validity questionable.** GA/AL means are lower pre-treatment (19.4% vs. FL's 24.1% high-dose share), and FL's epicenter status (98/100 top prescribers) suggests non-parallel baselines. Placebo (GA vs. AL) is reassuring but small-power; test controls' similarity via pre-trend matching or entropy balancing on observables (e.g., pharmacy counts, baseline volume). If unmatched, magnitudes may overstate effects.

### 4. Suggestions
**Strengthen visuals and diagnostics (priority for AER:Insights).** Add an event study figure (not just table)—plot pill-weighted coefficients with 95% CIs from WCB, shading pre/post periods. Include parallel trends plots stratified by volume terciles (high/mid/low) to visualize heterogeneity. A map of county-level treatment effects (shrinkage estimator) would spotlight South Florida concentration, making the "footprint" claim vivid.

**Expand robustness suite.** (i) Alternative thresholds: Report ≥20mg/≥40mg event studies in appendix table, as teased. (ii) Falsification: Event study hydrocodone-only share (should be null) and volume (benchmark vs. Alpert et al. 2018). (iii) Spillovers: Test negative effects in GA/AL border counties (e.g., 50-mile buffer). (iv) Jackknife by region (e.g., drop Broward/Miami-Dade). (v) Subsample high-volume counties only (>median pills), as unweighted hides effects—replicate main table.

**Refine specification details.** Year-month FEs with quarterly lags are fine but collinear at edges; use relative months or bin endpoints symmetrically. Clarify Post_t (July 2011): donut robustness helps, but discuss partial phasing (Oct 2010). Weights: Report weight distribution (e.g., top 5 counties' share ~X%) and Hansen-Sargan over-ID test for weighting endogeneity. Standardize all outcomes (as in appendix Table A6—promote to main) for comparability.

**Economic magnitudes and interpretation.** Effects are plausible (9.3pp aligns with smoke test 54%→31%; 0.68 SD large but credible for targeted crackdown). Quantify: -1.6mg/pill implies ~10% drop in MME conditional on volume, invisible in prior volume studies. Link to mortality: Regress county deaths on leads of high-dose share (instrumented?) to test "early warning." Discuss general equilibrium: Did high-dose shift to heroin/other states? (Tease PDMP extension.)

**Data and replication.** Excellent ARCOS details (matching rate, exclusions); add code link (GitHub exists). Balance table: Pre/post means by treatment/control/volume. Winsorize top 1% volume? Sample: Drop zero-pill county-months (23k obs implies some).

**Writing and AER fit.** Tight, punchy—ideal for Insights (23m execution!). Trim institutional background (merge subsubs). Abstract: Quantify "large" (e.g., 39% drop). JEL/keywords spot-on. Limitations honest; expand to "short post-period risks attenuation." Bigger picture: Position vs. Maclean et al. (2022) review—composition as new margin for supply interventions.

Overall, strong idea with clean execution; fixing inference/trends elevates to publishable. Reject threshold not met—promising draft.
